TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has granted inducement awards to a new employee. The grants, approved by the Compensation Committee, include:
- 336 non-qualified stock options with an exercise price of $156.00 per share
- 218 restricted stock units
The stock options will vest 25% after one year, with the remainder vesting monthly over three years. The restricted stock units will vest 25% annually over four years. Both grants are subject to continued employment and the terms of the TransMedics Group, Inc. Inducement Plan. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as material inducement for the employee's entry into employment with TransMedics.
TransMedics Group (Nasdaq: TMDX), una società di tecnologia medica focalizzata sulla terapia del trapianto d'organo, ha concesso premi di incentivo a un nuovo dipendente. I premi, approvati dal Comitato per la Compensazione, includono:
- 336 opzioni su azioni non qualificate con un prezzo di esercizio di $156,00 per azione
- 218 unità azionarie riservate
Le opzioni su azioni matureranno del 25% dopo un anno, con il resto che matura mensilmente per tre anni. Le unità azionarie riservate matureranno del 25% annualmente per quattro anni. Entrambi i premi sono soggetti a un impiego continuato e alle condizioni del Piano di Incentivo della TransMedics Group, Inc. Questi premi sono stati concessi in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) come incentivo materiale per l'ingresso del dipendente nella TransMedics.
TransMedics Group (Nasdaq: TMDX), una empresa de tecnología médica centrada en la terapia de trasplante de órganos, ha otorgado premios de inducción a un nuevo empleado. Los premios, aprobados por el Comité de Compensación, incluyen:
- 336 opciones de acciones no calificadas con un precio de ejercicio de $156.00 por acción
- 218 unidades de acciones restringidas
Las opciones de acciones se otorgarán en un 25% después de un año, con el resto otorgándose mensualmente durante tres años. Las unidades de acciones restringidas se otorgarán en un 25% anualmente durante cuatro años. Ambos premios están sujetos a la continuación del empleo y a los términos del Plan de Inducción de TransMedics Group, Inc. Estos premios se concedieron de acuerdo con la Regla de Cotización del Nasdaq 5635(c)(4) como un incentivo material para la incorporación del empleado a TransMedics.
TransMedics Group (Nasdaq: TMDX)는 장기 이식 치료에 중점을 둔 의료 기술 회사로, 새로운 직원에게 유인 보상을 지급했습니다. 보상은 보상 위원회의 승인을 받았으며, 내용은 다음과 같습니다:
- 주당 $156.00의 행사가격을 가진 336개의 비적격 주식 옵션
- 218개의 제한 주식 단위
주식 옵션은 1년 후에 25%가 확정되고, 나머지는 3년 동안 매달 확정됩니다. 제한 주식 단위는 4년 동안 매년 25%가 확정됩니다. 두 보상은 지속적인 고용과 TransMedics Group, Inc. 유인 계획의 조건에 따릅니다. 이 보상은 직원이 TransMedics에 입사하는데 있어 물질적 유인으로서 Nasdaq 상장 규칙 5635(c)(4)에 따라 부여되었습니다.
Le groupe TransMedics (Nasdaq: TMDX), une entreprise de technologie médicale axée sur la thérapie de transplantation d'organes, a accordé des récompenses d'incitation à un nouvel employé. Les récompenses, approuvées par le Comité de rémunération, incluent :
- 336 options d'actions non qualifiées avec un prix d'exercice de 156,00 $ par action
- 218 unités d'actions restreintes
Les options d'actions seront acquises à hauteur de 25 % après un an, le reste s'acquérant mensuellement sur trois ans. Les unités d'actions restreintes seront acquises à hauteur de 25 % par an pendant quatre ans. Les deux récompenses sont soumises à un emploi continu et aux conditions du Plan d'incitation de TransMedics Group, Inc. Ces récompenses ont été accordées conformément à la règle de cotation Nasdaq 5635(c)(4) en tant qu'incitation matérielle à l'entrée de l'employé chez TransMedics.
Die TransMedics Group (Nasdaq: TMDX), ein Medizintechnikunternehmen, das sich auf die Organtransplantationstherapie konzentriert, hat einem neuen Mitarbeiter Anreizprämien gewährt. Die Prämien, die vom Vergütungsausschuss genehmigt wurden, beinhalten:
- 336 nicht qualifizierte Aktienoptionen mit einem Ausübungspreis von 156,00 $ pro Aktie
- 218 eingeschränkte Aktieneinheiten
Die Aktienoptionen werden zu 25% nach einem Jahr fällig, der Rest monatlich über drei Jahre. Die eingeschränkten Aktieneinheiten werden zu 25% jährlich über vier Jahre fällig. Beide Prämien unterliegen der fortlaufenden Beschäftigung und den Bedingungen des Anreizplans der TransMedics Group, Inc. Diese Prämien wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als materieller Anreiz für den Eintritt des Mitarbeiters in die TransMedics gewährt.
- Attracting new talent with stock-based compensation
- Aligning employee interests with company performance through equity grants
- Potential dilution of existing shareholders' equity
TransMedics granted non-qualified stock options to purchase 336 shares of TransMedics' common stock and 218 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in
Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302260563.html
SOURCE TransMedics Group, Inc.
FAQ
What type of inducement grants did TransMedics (TMDX) offer on September 24, 2024?
What is the exercise price of the stock options granted by TransMedics (TMDX) on September 24, 2024?
How do the inducement grants made by TransMedics (TMDX) vest?
Under which Nasdaq rule did TransMedics (TMDX) grant these inducement awards?
